DACRA-042 / Eli Lilly, Nordic Biosci - LARVOL DELTA

Safety, tolerability and pharmacokinetic characterisation of DACRA KBP-042 in healthy male subjects. (PubMed, Br J Clin Pharmacol) - "The results of this study showed that doses up to 40 μg were safe, although tolerability was not present at the highest doses. The study confirmed target receptor engagement at the studied doses."

Clinical • Journal • PK/PD data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus